Skip to main content

Treating Bipolar 1 Disorder

By: 3BL Media

Healthcare professionals share perspectives on providing care for people living with bipolar 1 disorder

SOURCE: Alkermes

DESCRIPTION:

Check out a new infographic with findings from our latest survey conducted in partnership with The Harris Poll and Depression and Bipolar Support Alliance – National Headquarters. Learn what healthcare providers (HCPs) had to say about treating individuals with bipolar 1 disorder: https://bit.ly/383gMvq

About Alkermes
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Tweet me: .@Alkermes has created a new infographic from findings with @HarrisPoll and @DBSAlliance on what healthcare providers (HCPs) had to say about treating individuals with #bipolar 1 disorder: https://bit.ly/3FPKj8a

KEYWORDS: NASDAQ: ALKS, Alkermes

Text: Treating Bipolar 1 Disorder, Healthcare Professionals Share Perspectives on Providing Care for People Living with Bipolar 1 Disorder

Recent Quotes

View More
Symbol Price Change (%)
AMZN  236.65
-5.95 (-2.45%)
AAPL  259.96
-1.09 (-0.42%)
AMD  223.60
+2.63 (1.19%)
BAC  52.48
-2.06 (-3.78%)
GOOG  336.31
-0.12 (-0.04%)
META  615.52
-15.57 (-2.47%)
MSFT  459.38
-11.29 (-2.40%)
NVDA  183.14
-2.67 (-1.44%)
ORCL  193.61
-8.68 (-4.29%)
TSLA  439.20
-8.00 (-1.79%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.